Phase 1a/1b Study of Itacitinib (INCB039110) for Cytokine Release Syndrome Prevention and Minimization of Immunosuppression Following Nonmyeloablative Related Partially HLA-mismatched Peripheral Blood Stem Cell Transplant (PBSCT) With High-dose Posttransplantation Cyclophosphamide in Older Patients (Age 60 Years)
Latest Information Update: 10 Jul 2023
At a glance
- Drugs Itacitinib (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 06 Jul 2023 Status changed from not yet recruiting to recruiting.
- 17 May 2023 Planned initiation date changed from 1 Apr 2023 to 1 Jul 2023.
- 25 Apr 2023 New trial record